The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, $17 million research award to launch iCure Consortium to develop individualized “cure regimens” for HIV.
The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious disease, announces the appointment of Simon Chu, Ph.D., as Caspar Wistar Fellow in the Molecular…
PRESS RELEASE CONTACT: Darien Sutton 215-898-3988 | dsutton@wistar.org PHILADELPHIA — (July 10, 2025) — Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs…
Scientists at The Wistar Institute have discovered how a key protein from the Epstein-Barr virus (EBV), EBNA-LP, fundamentally rewires the three-dimensional structure of DNA in infected B cells to pr…
PHILADELPHIA — (May 28, 2025) — The Wistar Institute, a global leader in biomedical research in cancer, immunology and infectious disease, is pleased to welcome Joshua Friedman, M.D., Ph.D., to its B…
PHILADELPHIA — (May 22, 2025) — Researchers at The Wistar Institute have identified a previously unknown mechanism by which viruses can reprogram mitochondrial structure to silence immune responses a…
PHILADELPHIA — (April 30, 2025) —The Wistar Institute, a world leader in cancer, immunology, and infectious disease research, announces the appointment of Xiaoyu (Ariel) Zhou, Ph.D., as assistant pro…
PHILADELPHIA — (April 9, 2025) —The Wistar Institute’s Joseph Salvino, Ph.D., — in collaboration with Elton Zeqiraj, Ph.D., of The University of Leeds and Roger Greenberg, M.D., Ph.D., of The Perelma…
PHILADELPHIA — (March 21, 2025) — Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., in collaboration with scientists in the laboratory of Norbert Pardi, Ph.D., at the University of Pe…
